SLC17A8 and deafness: The earliest study on ear gene therapy commenced in 2012 and demonstrated partial restoration of hearing function in Vglut3‐deficient mice through AAV1‐mediated gene replacement therapy.[4] Since then, significant advancements have been made in the field of gene therapy for AAV‐mediated genetic deafness, further validating its feasibility in various deafness mouse models such as OtofΔ/Δ, Tmc1Y182C/Y182C, Tmc2Δ/Δ, StrcΔ/Δ, and Kcnq4W276S/+ (Table 4).